Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction.

Prathap KanagalaJayanth R ArnoldJamal N KhanAnvesha SinghGaurav S GulsinDaniel C S ChanAdrian S H ChengJing YangZhuyin LiPankaj GuptaIain B SquireGerry P McCannLeong L Ng

Published in: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2020)

In HFpEF, plasma Tenascin-C is higher compared to age- and sex-matched controls and a strong predictor of adverse outcomes. Trial registration: ClinicalTrials.gov: NCT03050593.

Keyphrases

clinical trial
study protocol
phase iii
randomized controlled trial
phase ii
double blind
placebo controlled
cone beam